Reduced plasma desmosterol-to-cholesterol ratio and longitudinal cognitive decline in Alzheimer's disease
| Autor: | Yoshiaki Sato, Lars Lannfelt, Takeshi Ikeuchi, Akinori Miyashita, Yasukazu Yamanaka, Ryozo Kuwano, Ken Aoshima, Martin Ingelsson, Yoshiya Oda, Francois Bernier |
|---|---|
| Jazyk: | angličtina |
| Předmět: |
medicine.medical_specialty
endocrine system Disease lcsh:Geriatrics lcsh:RC346-429 chemistry.chemical_compound Blood-based biomarker Desmosterol Internal medicine medicine In patient Cognitive decline Longitudinal biomarker lcsh:Neurology. Diseases of the nervous system Cholesterol Blood based biomarkers Mild cognitive impairment Blood‐based biomarker Alzheimer's disease Psychiatry and Mental health lcsh:RC952-954.6 Endocrinology chemistry Neurology (clinical) Psychology Neuroscience |
| Zdroj: | Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, Vol 1, Iss 1, Pp 67-74 (2015) |
| ISSN: | 2352-8729 |
| DOI: | 10.1016/j.dadm.2014.11.009 |
| Popis: | Background We here examined whether plasma desmosterol‐to‐cholesterol ratio (DES/CHO) is decreased in patients with Alzheimer's disease (AD) and investigated the association between plasma DES/CHO and longitudinal cognitive decline. Methods Plasma DES/CHO of AD patients and age‐matched controls in a Japanese cross‐sectional cohort was determined. Plasma DES/CHO at baseline and follow‐up visits was assessed in relation to cognitive decline in Japanese and Swedish longitudinal cohorts. Results Plasma DES/CHO was significantly reduced in Japanese AD patients and significantly correlated with Mini‐Mental State Examination (MMSE) score. The longitudinal analysis revealed that plasma DES/CHO in AD patients shows a significant decrease at follow‐up intervals. The decline in plasma DES/CHO is larger in the AD group with rapid progression than in that with slow progression. The changes in plasma DES/CHO significantly correlated with changes in the MMSE score. Conclusion Plasma DES/CHO is decreased in AD patients and may serve as a longitudinal surrogate marker associated with cognitive decline. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|